TY - JOUR
T1 - Polypoidal Choroidal Vasculopathy Based on Non-ICGA Criteria in White Patients With Neovascular Age-Related Macular Degeneration
AU - Chaikitmongkol, Voraporn
AU - Ozimek, Malgorzata
AU - Srisomboon, Titipol
AU - Patikulsila, Direk
AU - Fraser-Bell, Samantha
AU - Chhablani, Jay
AU - Choovuthayakorn, Janejit
AU - Watanachai, Nawat
AU - Kunavisarut, Paradee
AU - Rodríguez-Valdés, Patricio J.
AU - Lozano-Rechy, David
AU - Lupidi, Marco
AU - Al-Sheikh, Mayss
AU - Fung, Adrian T.
AU - Busch, Catharina
AU - Mehta, Hemal
AU - Gabrielle, Pierre Henry
AU - Zur, Dinah
AU - Ramon, Dan
AU - Sangkaew, Apisara
AU - Ingviya, Thammasin
AU - Amphornprut, Atchara
AU - Cebeci, Zafer
AU - Couturier, Aude
AU - Mendes, Thais Sousa
AU - Giancipoli, Ermete
AU - Iglicki, Matias
AU - Invernizzi, Alessandro
AU - Lains, Ines
AU - Rehak, Matus
AU - Sala-Puigdollers, Anna
AU - Okada, Mali
AU - Loewenstein, Anat
AU - Bressler, Neil M.
N1 - Funding Information:
Funding/Support: Funding for this study was provided by unrestricted donations to Johns Hopkins University for retina research. Financial Disclosures: V.C.: Bayer, Roche, Novartis; T.S.: Bayer; D.P.: Alcon, Bayer, Novartis; S.F.B.: Allergan, Bayer, Novartis, Roche; J.C.: Abbvie, Novartis, Salutaris; J.C.: Alcon, Allergan, Bayer, Novartis, Roche; N.W.: Alcon, Allergan, Bayer, Novartis; P.K.: Bayer, Novartis; P.J.R.: Allergan, Bayer, Industrial Organica, Novartis, Roche; D.L.: Allergan, Bayer, Novartis, Roche; M.L.: Allergan, Bayer, Heidelberg Engineering, Novartis, Roche; M.A.: Bayer, Novartis, financial support for protected research time: Filling The Gap, University of Zurich; A.F.: Alcon, Allergan, Bayer, Novartis, Roche, Syneos; C.B.: Abbvie, Allergan, Bayer, Novartis; H.M.: Allergan, Bayer, Novartis, Roche, P.-H.G.: Allergan, Bayer, Horus, Novartis, Zeiss; D.Z.: Abbvie, Allergan, Bayer, Novartis, Roche; A.C.: Abbvie, Alcon, Bayer, Roche, Novartis, Horus; E.G.: Allergan, Novartis; M.I.: Allergan, Bayer, Genentech, Novartis, Regeneron, TSK; A.I.: Allergan, Bayer, Novartis; M.R.: Allergan, Alimera, Bayer, Novartis, Zeiss; A.S.P.: Allergan, Bausch & Lomb, Bayer, Novartis; M.O.: Allergan, Roche; A.L.: AbbVie, Bayer, Beyeonics, NotalVision, Novartis, Roche, WebMD; N.M.B.: Bayer, Biogen, Novartis, Regeneron, Roche (Genentech), Samsung Bioepis, and unrestricted research funds to the Johns Hopkins University School of Medicine for Macular Degeneration and Related Diseases Research. The sponsor had no role in the design or conduct of this research. The other authors indicate no financial support or conflicts of interest. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/12
Y1 - 2022/12
N2 - PURPOSE: To determine prevalence of probable polypoidal choroidal vasculopathy (PCV) among White patients with neovascular age-related macular degeneration (nAMD) using non−indocyanine green angiography (ICGA) criteria DESIGN: Multicenter, multinational, retrospective, cross-sectional study. METHODS: A total of 208 treatment-naive eyes from Hispanic and non-Hispanic White individuals diagnosed with nAMD were included. All underwent color fundus photography (CFP), optical coherence tomography (OCT), and fluorescein angiography (FFA). De-identified images of study eyes were sent to 2 groups of graders. Group 1 reviewed CFP, OCT, and FFA to confirm nAMD diagnosis. Group 2 reviewed CFP and OCT to determine highly suggestive features for PCV. Probable PCV diagnosis defined as the presence of ≥2 of 4 highly suggestive features for PCV: notched or fibrovascular pigment epithelial detachment (PED) on CFP, sharply-peaked PED, notched PED, and hyperreflective ring on OCT. RESULTS: Eleven eyes were excluded because of poor image quality (6) or non-nAMD diagnosis (5). Of 197 eligible eyes (197 patients), the mean age (SD) was 78.8 years (8.9), 44.2% were men, 26.4% were Hispanic, and 73.6% were non-Hispanic White individuals; 41.1%, 23.4%, 9.1%, and 2.5% had ≥1, ≥2, ≥3, and 4 highly suggestive features. Results showed that 23.4% (95% CI, 17.6%-29.9%) had probable PCV diagnosis. Predominantly occult CNV was more frequently found in probable PCV than nAMD subgroup (84.8% vs 64.9%, P = .01). Hispanic White individuals had a lower prevalence of probable PCV than non-Hispanic White individuals (9.6% vs 28.2%, P = .006) CONCLUSIONS: These findings suggest that probable PCV occurs between 17.6% and 29.9% in White individuals with nAMD, and more commonly in non-Hispanic than in Hispanic White individuals.
AB - PURPOSE: To determine prevalence of probable polypoidal choroidal vasculopathy (PCV) among White patients with neovascular age-related macular degeneration (nAMD) using non−indocyanine green angiography (ICGA) criteria DESIGN: Multicenter, multinational, retrospective, cross-sectional study. METHODS: A total of 208 treatment-naive eyes from Hispanic and non-Hispanic White individuals diagnosed with nAMD were included. All underwent color fundus photography (CFP), optical coherence tomography (OCT), and fluorescein angiography (FFA). De-identified images of study eyes were sent to 2 groups of graders. Group 1 reviewed CFP, OCT, and FFA to confirm nAMD diagnosis. Group 2 reviewed CFP and OCT to determine highly suggestive features for PCV. Probable PCV diagnosis defined as the presence of ≥2 of 4 highly suggestive features for PCV: notched or fibrovascular pigment epithelial detachment (PED) on CFP, sharply-peaked PED, notched PED, and hyperreflective ring on OCT. RESULTS: Eleven eyes were excluded because of poor image quality (6) or non-nAMD diagnosis (5). Of 197 eligible eyes (197 patients), the mean age (SD) was 78.8 years (8.9), 44.2% were men, 26.4% were Hispanic, and 73.6% were non-Hispanic White individuals; 41.1%, 23.4%, 9.1%, and 2.5% had ≥1, ≥2, ≥3, and 4 highly suggestive features. Results showed that 23.4% (95% CI, 17.6%-29.9%) had probable PCV diagnosis. Predominantly occult CNV was more frequently found in probable PCV than nAMD subgroup (84.8% vs 64.9%, P = .01). Hispanic White individuals had a lower prevalence of probable PCV than non-Hispanic White individuals (9.6% vs 28.2%, P = .006) CONCLUSIONS: These findings suggest that probable PCV occurs between 17.6% and 29.9% in White individuals with nAMD, and more commonly in non-Hispanic than in Hispanic White individuals.
UR - http://www.scopus.com/inward/record.url?scp=85138518036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138518036&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2022.07.024
DO - 10.1016/j.ajo.2022.07.024
M3 - Article
C2 - 35952753
AN - SCOPUS:85138518036
SN - 0002-9394
VL - 244
SP - 58
EP - 67
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -